AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice

A securities class action alleges Aardvark Therapeutics told investors its drug was “99% gut-restricted,” had “no serious adverse events,” and would produce Phase 3 data in early 2026. Cardiac observations subsequently paused the HERO trial, and the FDA imposed a full clinical hold.